Global Health Limited (MEDANTA) Fair Value & Analysis
Healthcare · IN · Market cap ₹364B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price +12.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹961.10 – ₹1,427 · fair‑value band ₹328.27 – ₹548.60 · the ₹1,351 price screens above the ₹438.44 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Global Health Limited (MEDANTA) currently trades at ₹1,351, while our model-based Fair Value estimate is ₹438.44 — implying the stock looks roughly 67.5% overvalued today. We read business quality at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Global Health Limited generated revenue of ₹44.1B at a net margin of 12.6%. Revenue grew 24.5% year over year. It earns a return on equity of 15.0%. Net debt stands at ₹598M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Global Health Limited reported revenue of ₹44.1B in FY2026 versus ₹21.7B in FY2022, a compound +19.4%/yr. Reported net income was ₹5.6B in FY2026, compounding +29.8%/yr from FY2022.
Is MEDANTA fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.30 | $8.61 | -24% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.67 MYR | 3.08 MYR | -64% |
| IHHHF IHHHF | $1.71 | $0.7400 | -57% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Global Health Limited (MEDANTA) undervalued?
What is the fair value of MEDANTA?
What is the quality score of MEDANTA?
What is the revenue of Global Health Limited (MEDANTA)?
What is the net profit margin of MEDANTA?
Does Global Health Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.